Echt, Netherlands

Martin Schurmann

USPTO Granted Patents = 1 

Average Co-Inventor Count = 7.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2018

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Contributions of Martin Schurmann in Enzymatic Synthesis

Introduction

Martin Schurmann, an innovative inventor based in Echt, Netherlands, has made significant strides in the field of enzymatic synthesis. With one patent to his name, Schurmann presents groundbreaking methods that advance the production of enantiomerically enriched amines, contributing to various applications in biochemistry and pharmacology.

Latest Patents

Schurmann's notable patent titled "(R)-selective amination" reveals a method for the enzymatic synthesis of (R)-amines. This invention utilizes novel transaminases, sourced from specific proteins or isolated from certain microorganisms, to synthesize these important compounds from corresponding ketones. The detailed methodology showcased in his patent offers a valuable resource for researchers and industries focused on developing enantiomerically pure substances.

Career Highlights

At Patheon Holdings B.V., Schurmann plays an essential role in enhancing biopharmaceutical processes through innovative methodologies. His expertise in transaminases and enzymatic applications not only highlights his scientific acumen but also underscores his commitment to pushing the boundaries of current biotechnological practices.

Collaborations

Throughout his career, Martin Schurmann has collaborated with distinguished colleagues, including Wijnand Peter Helena Peeters and Natascha Hubertina Johannes Smeets. Together, they contribute to advancing the field using their collective knowledge and expertise in biochemistry and enzymatic processes.

Conclusion

Martin Schurmann's work, particularly in (R)-selective amination, illustrates the pivotal role of innovative thinking in the advancement of scientific knowledge and applications. His contributions at Patheon Holdings B.V. and collaborations with esteemed coworkers position him as a key figure in the ongoing evolution of enzymatic synthesis.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…